Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hypopituitarism
100%
Minneapolis
100%
Veterans Affairs Healthcare System
100%
Traumatic Brain Injury
100%
Humoral Hypercalcemia of Malignancy
100%
Primary Care Setting
100%
Fibroblast Growth Factor Receptor 1 (FGFR1)
100%
Intrahepatic Cholangiocarcinoma (iCCA)
100%
Cholangiocarcinoma
66%
Hypercalcemia
50%
Disease Progression
33%
Molecular Alterations
33%
Traumatic Brain Injury Patients
22%
Screening Rate
22%
High Index of Suspicion
16%
Zoledronic Acid
16%
Malignancy
16%
Locally Advanced
16%
Poor Clinical Outcomes
16%
Fibroblast Growth Factor Receptor Inhibitor
16%
Young Males
16%
Initial Diagnosis
16%
Targeted Therapy
16%
First Episode
16%
Parathyroid Hormone-related Protein (PTHrP)
16%
Hypercalcemia of Malignancy
16%
Risk Stratification
16%
Elevated Parathyroid Hormone
16%
Primary Care Clinic
11%
Pituitary Hormones
11%
Patient Data
11%
Brain Insult
11%
Endocrinology
11%
Hormonal Assay
11%
Screening Test
11%
Institutional Review Board
11%
Screening Criteria
11%
Random number Generator
11%
Screening Recommendations
11%
Retrospective Cohort Study
11%
Pituitary
11%
Quality of Life
11%
Health Problems
11%
Primary Care Physicians
11%
Clinic Setting
11%
Hormone Levels
11%
Single Center
11%
Consensus Guidelines
11%
Primary Care Providers
11%
Pituitary Infarction
11%
Medicine and Dentistry
Hypopituitarism
100%
Primary Health Care
100%
Health Care
100%
Cancer
100%
Hypercalcaemia
100%
Veterans Affairs
100%
Traumatic Brain Injury
100%
Cholangiocarcinoma
100%
Fibroblast Growth Factor Receptor
100%
Disease Exacerbation
20%
Hormone Determination
10%
Targeted Therapy
10%
Parathyroid Hormone-Related Protein
10%
Patient-Data
10%
Endocrinology
10%
Risk Stratification
10%
Zoledronic Acid
10%
Retrospective Cohort Study
10%
Screening Test
10%
Hypophysis Hormone
10%
Quality of Life
10%
Morbidity
10%
